Cardiology Stem Cells Market
Number of pages: 100 | Report Format: PDF | Published date: April 20, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 2.54 Billion |
|
Revenue Forecast in 2031 |
US$ 4.79 Billion |
|
CAGR |
7.32% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type of Cells, Source, Application, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global cardiology stem cells market was valued at US$ 2.54 billion in 2022 and is expected to register a revenue CAGR of 7.32% to reach US$ 4.79 billion by 2031.
Cardiology Stem Cells Market Fundamentals
Stem cells are undifferentiated cells that can differentiate into various cell types, including those of the heart. In cardiology, stem cells are being studied for their potential use in regenerative medicine, specifically for repairing damaged heart tissue. Cardiomyocytes, endothelial cells, and smooth muscle cells are the most common type of stem cells extensively studied in cardiology. Recently, induced pluripotent stem cells have been extensively investigated for their potential in cardiology therapeutics and research. These cells are created by converting adult cells into a pluripotent state, which allows them to develop into any cell type in the body, including cardiac cells. Researchers are investigating using iPSCs to generate patient-specific heart cells for transplantation or drug testing.
Additionally, the global cardiology stem cells market appears promising as regenerative medicine expands and improves. With an aging population and an increase in the frequency of heart disease, there is an increased demand for innovative treatments that can repair damaged heart tissue and enhance heart function.
Several market players in the cardiology stem cells market are developing strategic alliances and collaborations with other top companies, research institutes, and academic centers to harness their knowledge and resources in developing and commercializing stem cell therapeutics. This helps them get access to new markets and technologies and share the risks and costs of R&D. Several market participants are also considering mergers and acquisitions to diversify their product portfolios, acquire access to new technologies and markets, and boost their size and efficiency. This helps the companies to diversify their revenue streams.
[12]
Cardiology Stem Cells Market Dynamics
The increasing demand for regenerative medicine in cardiovascular diseases drives the global cardiology stem cells market revenue. Cardiac stem cell treatment has demonstrated the capacity to enhance cardiac function and minimize heart damage in preclinical and clinical investigations. Furthermore, this approach has shown promising results in preclinical and clinical studies for cardiovascular conditions such as heart failure and ischemic heart disease. Cardiac stem cell treatment has the potential to revolutionize the treatment of cardiovascular diseases, offering a regenerative approach that could improve outcomes for patients.
Advancements in cardiology stem cells approaches are increasingly supporting the revenue growth of the global cardiology stem cells market. During the last decade, several studies have investigated intracoronary bone marrow infusions in patients with acute myocardial infarction. Patients with acute myocardial infraction were administered an intracoronary infusion of ex vivo expanded bone marrow-derived mononuclear cells (BMMNCs) or culture-enriched endothelial progenitor cells (EPCs) generated from peripheral blood mononuclear cells (MNCs) in the Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction study.
Moreover, novel delivery systems for stem cell therapy are increasing the efficacy of cardiology stem cells. Such delivery systems include biomaterials and nanotechnology, which have shown promising results in preclinical studies. They offer targeted and sustained release of stem cells, improving their survival and integration into damaged heart tissue. Recently, there has been a greater emphasis on creating innovative biomaterials coated with stem cells and functionalized with growth, mitotic and chemotactic agents, cytokines, and other biologically active materials. These novel biomaterials are biocompatible and biodegradable polymers composed of poly (d, l-lactide-co-glycolide acid) or poly (lactic-co-glycolic acid) that enable longer and regulated supply of growth factors in situ as well as improved cell retention in the transplanted region. Combining stem cells, biomaterials, and growth factors may improve cell treatment effectiveness by mobilizing endogenous stem/progenitor cells in vivo, boosting cell proliferation and differentiation, and improving cell engraftment and survival in wounded myocardium.
However, the high cost associated with stem cell therapy and stringent regulatory guidelines for clinical trials is expected to restrain the revenue growth of the global cardiology stem cells market. However, ongoing research and development activities in this field will offer lucrative opportunities for market players during the forecast period.
Cardiology Stem Cells Market Ecosystem
The global cardiology stem cells market is analyzed from five perspectives: type of cells, source, application, end user, and region.
Cardiology Stem Cells Market by Type of Cells
Based on the type of cells, the global cardiology stem cells market is segmented into embryonic stem cells, cord blood stem cells and amniotic fluid stem cells, adult stem cells, and induced pluripotent stem cells.
The adult stem cells segment has dominated the global cardiology stem cells market with the largest revenue share. This dominance can be attributed to the increasing prevalence of cardiovascular diseases and the growing demand for effective treatment options. Moreover, adult stem cells can self-renew and specialize into a restricted number of mature cell types. This makes adult stem cells a promising solution for developing novel therapies for cardiovascular diseases. Adult stem cells can also be obtained from the patients, reducing the risk of rejection and other complications associated with traditional treatments.
Cord stem cells are a promising area of research for the cardiology stem cells market, as they have the potential to differentiate into various cardiac cell types and aid in repairing damaged heart tissue. However, further studies and clinical trials are needed to fully understand their effectiveness and safety in treating cardiovascular diseases.
Cardiology Stem Cells Market by Source
[14]
Based on the sources, the global cardiology stem cells market is segmented into autologous and allogeneic stem cells.
The Autologous segment accounted for most of the revenue share in 2022. Autologous stem cells are derived from the patient's body, while allogeneic stem cells are derived from donors. This segmentation is important for understanding the different applications and potential benefits of each type of stem cell therapy in cardiology. Autologous stem cells are less likely to be rejected by the patient's immune system. However, they may not be as effective in treating certain conditions.
Allogeneic stem cells have a higher risk of rejection but may have a greater potential for treating a wider range of cardiac conditions. The allogenic segment is expected to register a high revenue share during the forecast period. Allogenic stem cells have the advantage of being readily available. They can be obtained from a healthy donor, eliminating the need for harvesting from the patient. Additionally, allogeneic stem cells have been shown to have immunomodulatory properties that can reduce inflammation and improve cardiac function in patients with heart diseases.
Cardiology Stem Cells Market by Application
Based on application, the global cardiology stem cells market is segmented into heart failure, myocardial infarction, critical limb ischemia, and others.
The heart failure segment held a prominent revenue share of the market in 2022. This can be attributed to the rising prevalence of heart failure cases globally and the increasing demand for stem cell therapies for its treatment. Additionally, the growing awareness about the benefits of stem cell therapy in heart failure management is expected to drive the growth of this segment. The increasing geriatric population and the high prevalence of lifestyle diseases such as diabetes and hypertension are the major factors driving the growth of critical limb ischemia.
Cardiology Stem Cells Market by End User
Based on end-user, the global cardiology stem cells market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals & cell banks.
The hospitals & cell bank segment accounts for most of the global cardiology stem cells market revenue. This can be attributed to the increasing prevalence of cardiovascular diseases and the growing adoption of stem cell therapies in hospitals & cell banks.
The pharmaceutical and biotechnology companies segment is expected to show significant revenue growth during the forecast period due to the increasing investment in research and development activities. The development of innovative drugs and therapies also contributes to this segment's revenue growth. Furthermore, the increasing demand for personalized medicine and targeted therapies is expected to drive market revenue growth.
Cardiology Stem Cells Market by Region
Based on the region, the global cardiology stem cells market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the highest revenue share in 2022, attributed to well-established healthcare infrastructure, the high prevalence of cardiovascular diseases, and the high adoption of stem cell therapies in North America. Moreover, the presence of top market players in the region influences North America's cardiology stem cells market revenue growth.
The European cardiology stem cells market is characterized by increasing healthcare standards and research activities on cardiology stem cells. Technological advancements in stem cell research are also expected to drive market revenue growth in Europe.
The Asia Pacific region is expected to grow rapidly in terms of global market revenue during the forecast period due to the increasing number of academic and research institutes. Asia Pacific governments invest heavily in developing healthcare settings with advanced treatment options. Moreover, rising medical research outsourcing to the CROs in the region for developing advanced treatments in the Asia Pacific is increasing the global cardiology stem cells market revenue share.
Cardiology Stem Cells Market Competitive Landscape
The stem cell market is constantly evolving with the entry of new players and technological advancements. Key players in the market are focusing on strategic collaborations, partnerships, and mergers & acquisitions to strengthen their market position and expand their product portfolio.
The prominent companies operating in the global cardiology stem cells market with the largest revenue share are,
Cardiology Stem Cells Market Strategic Developments
Cardiology stem cells refer to the stem cells that have the potential to differentiate into various types of heart cells, such as cardiomyocytes, endothelial cells, and smooth muscle cells.
The global cardiology stem cells market is expected to be valued at US$ 4.79 billion by 2031.
The global cardiology stem cells market revenue is driven by the increasing prevalence of cardiovascular diseases and the growing demand for regenerative and personalized medicine.
The global cardiology stem cells market is expected to register a revenue CAGR of 7.32% by 2031
North America accounted for the highest revenue share in 2022 in the global cardiology stem cells market.
*Insights on financial performance are subject to the availability of information in the public domain